Dendreon (DNDN) – Insiders' Blog
-
Dendreon's (DNDN) Provenge Sales May be Slumping...
-
Dendreon (DNDN) Said to Artifically Inflate Provenge Data in 2010 Report - Reuters
-
Dendreon (DNDN) Is Not Yet a 'Buy', But It's Getting Close
-
Takeover Target Dendreon (DNDN) Rips Higher
-
Dendreon (DNDN) Spikes Higher into the Close
-
Traders Watching Regeneron (REGN) Following Amgen (AMGN) AMG 145 Results
-
Dendreon (DNDN) Pushes Higher, Now Up About 6%
-
Solar Rules, Retail Drools Early in 2012 (TAN) (XRT)
-
Oncothyreon (ONTY) Surges into Positive Territory
-
Dendreon (DNDN) Rips into Positive Territory, Now Up 3.9%
-
Heading into Q311, Here are Top Five Q211 Earnings Winners and Losers
-
Amid 65% Decline in Dendreon (DNDN) Shares, Not All Analysts Bearish
-
Wall Street Hubbub 9/8: Netezza (NZ) Jumps On Takeover Chatter, ArcSight (ARST) Falls As Sale Hits Snag, New York Times (NYT) Re-Enters the Rumor Mill
-
Wall Street Hubbub 7/15: JPMorgan's Earnings Quality "Weak", BP On Verge of Asset Sale, AIG's Benmosche Makes More Waves, iPhone 4 Fiasco
-
Denderon (DNDN) Falls On Negative Research Paper
-
Dendreon (DNDN) 17% 4-Day Jump Raises Eyebrows; Is a Deal in the Works?
-
Dendreon (DNDN) Sinks As CMS Weighs Provenge Coverage
-
Wall Street Giddy About Dendreon (DNDN) After Provenge Approval; Where Are Shares Headed?
-
Investors "Generally Protective" Into Dendreon (DNDN) May 1 PDUFA Date
-
'Takeover Fever' Continues In Biotech After Facet (FACT) Deal, Who's Next?
-
New Dendreon (DNDN) Board Member Disclosures Revs Up Rumor Mill
-
Dendreon (DNDN) Higher On Renewed Takeover Talk
-
Reports Dendreon (DNDN) Has Hired A Financial Advisor
-
Stock, Stock Everywhere!! May Stock Offerings Already Exceed $30 Billion
-
Dendreon (DNDN) Sees Continued Upside On 'Table-Pounding' Analyst Comments
-
Dendreon (DNDN) Insiders Unload Shares After Positive Trial Results
-
Brean Murray's Late To The Game Dendreon (DNDN) Analyst Defends Himself On Fast Money
-
Needham Upgrades Dendreon (DNDN) To Buy, With 'Street High' $38 Price Target
-
Dendreon (DNDN) Bear Now A Full-Fledged Bull
-
Wachovia Upgraded Dendreon (DNDN) to Outperform, Expects PROVENGE Approval
-
Shorts Have One Last Hurrah In Dendreon (DNDN) Before Positive Trial Details
-
Dendreon (DNDN) Higher Ahead of Details of PROVENGE IMPACT Study
-
Bearish Dendreon (DNDN) Analyst Throws In The Towel, Upgrades to Hold
-
FDA Could Request Additional Confirmatory Trial For Dendreon's (DNDN) Provenge
-
Dendreon (DNDN) Opens Up At $25
-
Brean Murray Comments on Dendreon (DNDN) Following Friday's Run-Up
-
Dendreon (DNDN) Spikes On Presentation News
-
Wachovia Cautious on Interim Data from Dendreon's (DNDN) Provenge Trial; Says Rally Will Be 'Short-Lived'
Back to DNDN Stock Lookup